Skip to main content

ORTHOPEDIATRICS CORP

For the period ended Dec 31, 2024. Filed Mar 5, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 5, 2025

KIDS$33.99+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-K

[Mark One]

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number 001-38242

(Exact name of registrant as specified in its charter)

Delaware26-1761833
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)
2850 Frontier DriveWarsaw, Indiana46582
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (574)268-6379

Securities registered pursuant to Section 12(b) of the Act:

Title of Each ClassTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.00025 par value per shareKIDSNasdaq Global Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes¨ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes¨ No ☒

Indicate by check mark whether the registrant(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No¨

Indicate by check mark whether the registrant has submitted electronically every interactive data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)Yes ☒ No¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer¨Accelerated filer ☒Non-accelerated filer¨ Smaller Reporting Company¨ Emerging Growth Company¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.¨

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.¨

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes☐ No☒

The aggregate market value of the registrant's common stock held by non-affiliates of the registrant was approximately $263.4 million as of the last business day of the registrant's most recently completed second fiscal quarter (June 30, 2024), based upon the closing sale price for the registrant's common stock on that day as reported by the Nasdaq Global Market. Shares of common stock held by each officer and director of the registrant and by each person who owns 10 percent or more of outstanding common stock on June 30, 2024 have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily conclusive for other purposes.

As of March 1, 2025, the registrant had 24,286,590 outstanding shares of common stock, $0.00025 par value per share.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.

Statement Regarding Forward-Looking Statements6
Risk Factor Summary7
PART I
Item 1.Business8
Item 1A.Risk Factors32
Item 1B.Unresolved Staff Comments71
Item 1C.Cybersecurity71
Item 2.Properties72
Item 3.Legal Proceedings72
Item 4.Mine Safety Disclosures72
PART II
Item 5.Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities73
Item 6.[Reserved]74
Item 7.Management's Discussion and Analysis of Financial Condition and Results of Operations75
Item 7A.Quantitative and Qualitative Disclosure about Market Risk85
Item 8.Financial Statements and Supplementary Data86
Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure123
Item 9A.Controls and Procedures123
Item 9B.Other Information124
Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections124
PART III
Item 10.Directors, Executive Officers and Corporate Governance125
Item 11.Executive Compensation125
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters125
Item 13.Certain Relationships, Related Transactions and Director Independence125
Item 14.Principal Accountant Fees and Services125
PART IV
Item 15.Exhibits and Financial Statement Schedules126

Glossary of Acronyms and Defined Terms

ACLAnterior cruciate ligament
ApiFixThe combination of ApiFix, Ltd and ApiFix, Inc., which were acquired by the Company on April 1, 2020
Approved BodyAn approved body under UK medical Device Regulations
Band-LokBand-Lok, LLC, which sold certain intellectual property assets to the Company on June 10, 2020
Boston O&PBoston Brace International, Inc., which was acquired by the Company on January 5, 2024
CE MarkConformite Europeene Mark used for medical devices in the EEA; a product with such a mark is referred to herein as a "CE-Marked" product.
CMEContinuing medical education
CMSCenters for Medicare and Medicaid Services
CompanyOrthoPediatrics Corp.
Convertible Notes$50 million of 4.75% Convertible Senior Notes due 2030 that were sold to Braidwell Transaction Holdings LLC – Series 10 on August 5, 2024
DHHSU.S. Department of Health and Human Services
EEAEuropean Economic Area
EUEuropean Union
Exchange ActU.S. Securities Exchange Act of 1934
FDAU.S. Food and Drug Administration
FDASIAFood and Drug Administration Safety and Innovation Act
FDCAFederal Food, Drug and Cosmetic Act
FERAFraud Enforcement Recovery Act of 2009
FoundationThe Foundation for Advancing Pediatric Orthopedics
GAAPU.S. Generally Accepted Accounting Principles
GDPREU General Data Protection Regulation
HCPHealthcare providers
HDEHumanitarian Device Exemption under FDA regulation
HIPAAHealth Insurance Portability and Accountability Act of 1996
IPOCompany’s initial public offering of its common stock on October 11, 2017
IRBInstitutional Review Board utilized by the FDA
LLDLimb length discrepancies
Loan AgreementFourth Amended and Restated Loan and Security Agreement with Squadron Capital LLC (terminated effective as of December 29, 2023), which provided the Company with a $50.0 million revolving credit facility
MDDMedical Devices Directive
MD Ortho or MDOMD Orthopaedics, which was acquired by the Company on April 1, 2022
MDREU’s Medical Device Regulation
MHRAMedicines and Healthcare products Regulatory Agency of the United Kingdom
MidCap Credit AgreementCredit, Security and Guaranty Agreement with MidCap Financial Trust, asamended from time to time, which provided the company with a $50 million line of credit and a $30 million term loan. Terminated August 5, 2024.
MPFLMedial petellofemoral ligament
O&POrthotic and prosthetic
OrthexOrthex, LLC, which was acquired by the Company on June 4, 2019
Pega Medical or PegaPega Medical Inc., which was acquired by the Company on July 1, 2022
PMAPremarket Approval Application with the FDA
PNPPediatric Nailing Platform
PODPhysician-owned distributorships
POSNAPediatric Orthopaedic Society of North America
QSRFDA’s Quality System Regulation
RSVRespiratory Syncytial Virus, a respiratory virus commonly impacting children
SECUnited States Securities and Exchange Commission
SquadronSquadron Capital LLC, which is the Company’s largest investor
Structure MedicalStructure Medical, LLC
TelosTelos Partners, LLC, which was acquired by the Company on March 9, 2020
Term Loan AgreementCredit Agreement and Guaranty with Braidwell LP which provides the Company with an initial $25 million and access to a delayed draw term loan facility for an additional $25 million.
UK or United KingdomThe United Kingdom of Great Britain and Northern Ireland
UKCA MarkUK Conformity Assessed marking is a new UK product marking that is used for goods being placed on the market in Great Britain (England, Wales and Scotland)
VilexVilex in Tennessee, Inc., which was acquired by the Company on June 4, 2019 and substantially all its assets were sold on December 31, 2019 to a wholly-owned subsidiary of Squadron Capital, LLC
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.